Can digital tools help cell and gene therapy evolve?

Download our eBook to find out how the industry is trying to be more sustainable.

Ulrike Gnad-Vogt talks us through CureVac’s efforts to target seasonal influenza

Check out our video interview covering decentralized manufacturing and more.

As the world continues to take on the post-COVID flu epidemic, we ask RQ Bio CEO Hugo Fry what part monoclonal antibodies play in new flu treatments

Why 2023 is the year that antibody manufacturers should embrace CRISPR gene editing.

An early wave of investor enthusiasm followed by an economic crisis has landed our field in a sea of trouble – so how can we swim to shore?

AI for drug discovery has enormous potential; to unlock it, we need to reset our mindset

The first Humira biosimilar in the US is here, but market penetration could be a challenge.

Gene Sullivan, Chief Product Strategy Officer at Insmed, explores how new thinking could improve the research process for rare disease treatments